BRPI0415562B8 - método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio - Google Patents

método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio

Info

Publication number
BRPI0415562B8
BRPI0415562B8 BRPI0415562A BRPI0415562A BRPI0415562B8 BR PI0415562 B8 BRPI0415562 B8 BR PI0415562B8 BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 B8 BRPI0415562 B8 BR PI0415562B8
Authority
BR
Brazil
Prior art keywords
carcinoma
lap
prognostic
immunoassay kit
patient
Prior art date
Application number
BRPI0415562A
Other languages
English (en)
Inventor
Mizutani Shigehiko
Original Assignee
Suntory Holdings Ltd
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd, Suntory Ltd filed Critical Suntory Holdings Ltd
Publication of BRPI0415562A publication Critical patent/BRPI0415562A/pt
Publication of BRPI0415562B1 publication Critical patent/BRPI0415562B1/pt
Publication of BRPI0415562B8 publication Critical patent/BRPI0415562B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma. a presente invenção proporciona um reagente para avaliação prognóstica de pacientes com carcinoma, compreendendo um anticorpo anti-p-lap como um ingrediente ativo. também, a presente invenção proporciona um método para a determinação de p-lap que é um fator prognóstico em pacientes com carcinoma compreendendo (a) uma etapa de contatar tecidos de carcinoma obtidos de pacientes com carcinoma por operação cirúrgica com um anticorpo anti-p-lap e (b) uma etapa de medir a intensidade da reação específica de antígeno-anticorpo entre p-lap presente nos tecidos de carcinoma e o anticorpo anti-p-lap.
BRPI0415562A 2003-10-21 2004-09-15 método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio BRPI0415562B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003360638 2003-10-21
JP2003-360638 2003-10-21
PCT/JP2004/013883 WO2005038462A1 (en) 2003-10-21 2004-09-15 Method for prognostic evaluation of carcinoma using anti-p-lap antibody

Publications (3)

Publication Number Publication Date
BRPI0415562A BRPI0415562A (pt) 2007-01-02
BRPI0415562B1 BRPI0415562B1 (pt) 2020-02-04
BRPI0415562B8 true BRPI0415562B8 (pt) 2021-07-27

Family

ID=34463417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415562A BRPI0415562B8 (pt) 2003-10-21 2004-09-15 método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio

Country Status (5)

Country Link
US (1) US7666605B2 (pt)
JP (1) JP4635004B2 (pt)
BR (1) BRPI0415562B8 (pt)
CA (1) CA2542823C (pt)
WO (1) WO2005038462A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007209725A1 (en) * 2006-01-24 2007-08-02 Sirius Genomics Inc. Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects
US7689554B2 (en) * 2006-02-28 2010-03-30 Yahoo! Inc. System and method for identifying related queries for languages with multiple writing systems
FR2933411B1 (fr) 2008-07-04 2013-04-19 Univ Joseph Fourier Utilisation de la proteine irap pour la mise en oeuvre de methodes de diagnostic et de pronostique
FR2945808B1 (fr) * 2009-05-20 2013-12-27 Univ Joseph Fourier Peptides marques et leur utilisation pour le dosage d'irap circulant
JP7313005B2 (ja) * 2019-06-25 2023-07-24 医療法人三栄会 がんのバイオマーカーおよびがんの発症を判定する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4129704B2 (ja) * 1998-09-22 2008-08-06 ニプロ株式会社 ロイシンアミノペプチダーゼ活性測定用試薬

Also Published As

Publication number Publication date
US7666605B2 (en) 2010-02-23
US20070020705A1 (en) 2007-01-25
WO2005038462A1 (en) 2005-04-28
JP2007509313A (ja) 2007-04-12
CA2542823A1 (en) 2005-04-28
JP4635004B2 (ja) 2011-02-16
BRPI0415562A (pt) 2007-01-02
CA2542823C (en) 2015-05-26
BRPI0415562B1 (pt) 2020-02-04

Similar Documents

Publication Publication Date Title
CY1120296T1 (el) ΔΙΑΛΥΤΟΣ ΥΠΟΔΟΧΕΑΣ ΕΝΕΡΓΟΠΟΙΗΤΗ ΤΟΥ ΠΛΑΣΜΙΝΟΓΟΝΟΥ ΤΥΠΟΥ ΟΥΡΟΚΙΝΑΣΗΣ (suPAR) ΩΣ ΔΙΑΓΝΩΣΤΙΚΟΣ ΔΕΙΚΤΗΣ ΓΙΑ ΧΑΜΗΛΟΥ ΒΑΘΜΟΥ ΦΛΕΓΜΟΝΗ
BRPI0412725B8 (pt) marcadores para detecção de câncer gástrico
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
ATE438853T1 (de) Diagnostische testvorrichtung
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
BR112017021305A2 (pt) dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva
EP2319941A3 (en) Method and apparatus for correlating levels of biomarker products with disease
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
ATE550649T1 (de) Testvorrichtung für analyten mit vielseitiger verwendungsmöglichkeit
NO992624D0 (no) Refleksalgoritme for tidlig og kostnadseffektiv diagnose av myokardialt infarkt som er egnede for atomatiserte diagnostiske innretninger
ATE289685T1 (de) Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
EP1839056A4 (en) Preeclampsia-DIAGNOSIS
EP1836956A3 (en) Activity-induced energy expenditure estimating instrument
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
BRPI0509978A (pt) uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas
ATE369564T1 (de) Differenzielles immunoassay für myoglobin
WO2008060376A3 (en) Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
BR9913770A (pt) Processo de ensaio para determinação da cobalamina ligada a transcobalamina ii (tcii) em uma amostra de corpo, kit para uso em um ensaio diagnóstico, e, uso de holo-tc ii
ATE406579T1 (de) Verfahren zur diagnose von tumoren
ATE412180T1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
WO2022241292A3 (en) Use of markers in the diagnosis and treatment of parkinson's disease

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SUNTORY HOLDINGS LIMITED (JP)

Free format text: TRANSFERIDO DE: SUNTORY LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO